Diabetes mellitus is a complex metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The global burden of diabetes continues to rise, prompting an urgent need for biomarkers that can facilitate early diagnosis, risk stratification, and personalized management. While traditional markers such as fasting glucose and hemoglobin A1c remain cornerstones of diabetes care, they often reflect relatively late-stage metabolic disturbances. Recent research has focused on identifying biomarkers that capture the underlying inflammatory and metabolic dysregulation that precedes and accompanies the disease. One such promising biomarker is serum visfatin, an adipokine with pleiotropic effects on inflammation and energy metabolism. Its unique position at the intersection of immunity and metabolism makes it a compelling candidate for improving our understanding and clinical management of diabetes.

What is Serum Visfatin?

Serum visfatin, also known as nicotinamide phosphoribosyltransferase (NAMPT), is an enzyme and adipokine predominantly secreted by visceral adipose tissue. Its discovery highlighted the active endocrine role of fat tissue beyond simple energy storage. Visfatin exists in two forms: an intracellular form that functions as NAMPT, catalyzing the rate-limiting step in NAD+ biosynthesis, and an extracellular form that acts as a cytokine-like molecule. This dual identity allows visfatin to bridge cellular energy metabolism with systemic inflammatory responses. The intracellular pool is essential for maintaining NAD+ levels, which are critical for redox reactions and energy production, while the secreted form can bind to receptors such as the insulin receptor and toll-like receptor 4 (TLR4), triggering downstream signaling cascades.

Elevated levels of visfatin have been consistently observed in individuals with metabolic disorders, especially type 2 diabetes and obesity. Its secretion is stimulated by pro-inflammatory signals, hyperglycemia, and oxidative stress. As an adipokine, visfatin contributes to the crosstalk between adipose tissue and other organs, including the liver, skeletal muscle, and the immune system. Understanding its biology is key to appreciating its potential as a biomarker. The regulation of visfatin expression involves several transcription factors, including HIF-1α under hypoxic conditions and NF-κB in response to inflammation, linking it directly to the pathological milieu of diabetes.

Visfatin in Inflammation and Metabolism

Visfatin is deeply involved in both inflammatory and metabolic pathways, making it a unique marker of the interface between these two systems. Its actions are mediated through multiple mechanisms, including direct cytokine-like effects and modulation of cellular energy status via NAD+ production. This section details the specific roles visfatin plays in each domain.

Role in Inflammatory Pathways

Visfatin stimulates the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). It activates nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling cascades in immune cells and endothelial cells. These pathways are central to the chronic low-grade inflammation that characterizes obesity and type 2 diabetes. Elevated visfatin levels correlate with increased circulating levels of inflammatory markers like high-sensitivity C-reactive protein (hs-CRP). The ability of visfatin to promote monocyte chemotaxis and macrophage activation further amplifies the inflammatory response within adipose tissue.

In the context of diabetes, this inflammatory dysregulation exacerbates insulin resistance. Adipose tissue macrophages, recruited and activated by visfatin, produce cytokines that interfere with insulin signaling in adipocytes and hepatocytes. For instance, TNF-α can phosphorylate serine residues of IRS-1, blunting insulin action. Thus, serum visfatin serves as a proxy for the inflammatory burden within adipose tissue and the systemic milieu. Emerging evidence also suggests that visfatin can induce endothelial cell activation, promoting the expression of adhesion molecules such as ICAM-1 and VCAM-1, which facilitates leukocyte extravasation and contributes to vascular inflammation in diabetic complications.

Role in Metabolic Regulation

Visfatin influences glucose and lipid metabolism through several routes. It has insulin-mimetic properties, promoting glucose uptake in adipocytes and myocytes via activation of the insulin receptor and downstream signaling. However, at high concentrations, chronic visfatin exposure may desensitize cells to insulin, contributing to insulin resistance. This paradoxical effect is reminiscent of other insulin sensitizing hormones that become detrimental when chronically elevated. Additionally, visfatin modulates lipid metabolism by promoting lipogenesis and inhibiting lipolysis in adipose tissue, further linking it to metabolic dysregulation. In hepatocytes, visfatin can stimulate gluconeogenesis and lipid accumulation, potentially driving fatty liver disease.

As a rate-limiting enzyme in NAD+ synthesis, visfatin impacts cellular redox status and energy metabolism. NAD+ is essential for glycolysis, the Krebs cycle, and oxidative phosphorylation. Dysregulation of NAD+ homeostasis is implicated in metabolic diseases and aging. By regulating NAD+ availability, visfatin influences the activity of sirtuins and PARP enzymes, which are key sensors of metabolic stress. Therefore, serum visfatin levels reflect not only adipokine secretion but also systemic metabolic health. The interplay between NAD+ biosynthesis and inflammation creates a feedback loop where metabolic dysfunction drives inflammation and vice versa.

Inflammatory Dysregulation in Diabetes: The Role of Visfatin

Increased serum visfatin levels are robustly associated with heightened inflammatory responses in diabetic patients. This inflammatory dysregulation is a hallmark of type 2 diabetes and contributes to complications such as cardiovascular disease, nephropathy, and retinopathy. Measuring visfatin levels can provide insights into the inflammatory status of diabetic individuals beyond what is captured by standard markers.

Studies have shown that visfatin levels are elevated in patients with type 2 diabetes compared to healthy controls, and that these levels correlate positively with markers of inflammation and oxidative stress. In a meta-analysis of 20 studies, circulating visfatin concentrations were significantly higher in diabetic patients, and the association remained after adjusting for body mass index. This suggests that visfatin is not merely a reflection of adiposity but an independent marker of inflammatory dysregulation. The relationship holds across different ethnicities and populations, reinforcing its potential generalizability.

Furthermore, visfatin may play a direct role in diabetic complications. It promotes endothelial dysfunction by inducing adhesion molecule expression and increasing vascular permeability. In the kidney, visfatin contributes to podocyte injury and albuminuria. In the retina, visfatin has been linked to retinal neovascularization and inflammation. These findings underscore the utility of visfatin as a biomarker for both systemic inflammation and organ-specific damage in diabetes. For instance, elevated serum visfatin has been independently associated with increased carotid intima-media thickness and higher rates of cardiovascular events in diabetic cohorts.

Metabolic Dysregulation: Visfatin as a Marker of Glycemic Control and Insulin Resistance

Visfatin's role in metabolic regulation makes it a valuable biomarker for assessing metabolic health. Elevated visfatin levels correlate with poor glycemic control, as measured by fasting glucose and hemoglobin A1c, and with insulin resistance indices such as HOMA-IR. Monitoring these levels can help in evaluating the severity of metabolic dysregulation and tailoring treatment strategies. In cross-sectional studies, visfatin levels have also been linked to dyslipidemia, especially elevated triglycerides and low HDL cholesterol.

In longitudinal studies, baseline visfatin levels predicted incident type 2 diabetes in normoglycemic individuals, independent of obesity and other risk factors. This suggests that visfatin secretion is an early event in the pathogenesis of diabetes. Moreover, weight loss interventions that improve insulin sensitivity often lead to reductions in circulating visfatin, indicating that it can serve as a marker of therapeutic response. Similarly, bariatric surgery results in significant drops in visfatin levels that parallel improvements in glycemic control.

However, the relationship between visfatin and metabolic parameters is complex. Some studies have reported contradictory findings, particularly regarding the association with body mass index. These discrepancies may arise from differences in assay methods, sample size, and population characteristics. Standardization of measurement techniques is essential for reliable clinical use. Despite these challenges, the weight of evidence supports visfatin as a clinically relevant indicator of metabolic dysregulation.

Clinical Evidence and Studies

Numerous clinical studies have investigated the association between serum visfatin and diabetes. For example, a study published in Diabetes Care found that visfatin levels were significantly higher in patients with type 2 diabetes compared to controls, and that levels correlated with markers of insulin resistance and inflammation. Another study in Metabolism reported that visfatin was independently associated with carotid intima-media thickness, a surrogate marker of atherosclerosis, in diabetic patients. More recently, a large cohort study from China demonstrated that elevated visfatin at baseline predicted the development of diabetic kidney disease over a 5-year follow-up period.

"Serum visfatin levels are elevated in type 2 diabetes and correlate with insulin resistance and inflammatory markers, suggesting that visfatin may serve as a useful biomarker for the metabolic and inflammatory dysregulation that accompanies the disease."

A recent systematic review and meta-analysis of observational studies confirmed that circulating visfatin levels are higher in individuals with type 2 diabetes, with a standardized mean difference of 0.85. Subgroup analyses indicated that the association was stronger in studies using enzyme-linked immunosorbent assays (ELISA) compared to other methods, highlighting the need for assay standardization. The same meta-analysis found that visfatin levels were positively correlated with fasting glucose and HOMA-IR, providing quantitative support for its role in metabolic dysregulation.

In gestational diabetes mellitus (GDM), visfatin levels are also elevated and correlate with adverse pregnancy outcomes such as macrosomia and neonatal hypoglycemia. This expands the potential clinical utility of visfatin to other forms of diabetes. Additionally, studies in type 1 diabetes have shown mixed results, with some reporting elevated visfatin in association with autoimmunity, suggesting that its role may extend beyond insulin resistance to beta-cell dysfunction.

Potential Mechanisms Linking Visfatin to Diabetic Dysregulation

Several molecular mechanisms explain how visfatin contributes to inflammatory and metabolic dysregulation in diabetes:

  • NF-κB activation: Visfatin binds to TLR4 and activates NF-κB (as well as downstream MAPK pathways), leading to transcription of pro-inflammatory cytokines. This signaling is also implicated in insulin resistance via JNK-mediated IRS-1 serine phosphorylation.
  • Insulin receptor modulation: Extracellular visfatin can bind to the insulin receptor and activate Akt signaling, mimicking insulin action. However, at supraphysiological concentrations, it induces insulin resistance through receptor desensitization and chronic activation of negative feedback loops such as SOCS3.
  • NAD+ depletion: Intracellular visfatin activity is essential for NAD+ synthesis. In states of metabolic stress, NAD+ levels drop, impairing mitochondrial function and promoting oxidative stress. The resulting increase in reactive oxygen species activates further inflammatory signaling, creating a vicious cycle.
  • Adipose tissue remodeling: Visfatin promotes angiogenesis and macrophage infiltration in adipose tissue, perpetuating a cycle of inflammation and dysfunction. By stimulating the production of chemokines like MCP-1, visfatin recruits immune cells that release more inflammatory mediators.
  • Endothelial dysfunction: Visfatin upregulates adhesion molecules and impairs nitric oxide bioavailability, contributing to the vascular pathology seen in diabetic complications. This mechanism involves activation of the RhoA/ROCK pathway.

These mechanisms position visfatin as a hub linking metabolism and immunity, making its measurement informative for both dimensions of diabetes. The interconnected nature of these pathways suggests that targeting visfatin could have pleiotropic benefits.

Clinical Implications and Applications

Using serum visfatin as a biomarker offers several potential clinical benefits:

  • Early detection: Elevated visfatin levels may identify individuals at high risk for developing type 2 diabetes, even in the absence of overt hyperglycemia. This could enable earlier lifestyle or pharmacological interventions, potentially preventing progression from prediabetes to diabetes.
  • Monitoring disease progression: Serial measurements of visfatin could track the evolution of insulin resistance and inflammation over time, complementing standard glycemic markers. For instance, rising visfatin might signal worsening metabolic health before A1c changes become apparent.
  • Guiding therapy: Patients with high visfatin levels may benefit from anti-inflammatory treatments or drugs that modulate NAD+ metabolism. For instance, metformin has been shown to reduce visfatin levels in some studies, suggesting a potential mechanism for its anti-inflammatory effect. Other agents like pioglitazone and GLP-1 receptor agonists also lower visfatin, which may contribute to their metabolic benefits.
  • Risk stratification: Visfatin levels could help stratify patients according to their risk of diabetic complications, particularly cardiovascular disease and nephropathy. Combining visfatin with other biomarkers (e.g., hs-CRP) may improve predictive accuracy for adverse outcomes.

Challenges and Limitations

Despite its promise, several hurdles must be overcome before visfatin can be adopted in clinical practice:

  • Assay variability: Different methods (ELISA, radioimmunoassay, mass spectrometry) yield different absolute values, and there is no internationally standardized reference material. This complicates comparison across studies and establishment of reference ranges. The need for a reference standard is urgent.
  • Confounding factors: Visfatin levels are influenced by age, sex, body fat distribution, and renal function. For instance, visfatin is cleared by the kidneys, so levels increase in chronic kidney disease, which is common in diabetes. This may confound the association with metabolic parameters. Additionally, physical activity and medication use can affect levels.
  • Circadian variation: Some reports suggest that visfatin exhibits diurnal variation, with peak levels in the morning, which could affect the timing of measurements and comparability.
  • Causal vs. correlative role: While visfatin is correlated with diabetes, its causal role remains debated. Some studies suggest that visfatin is a compensatory response to metabolic stress rather than a driver of disease. For example, NAMPT activity is critical for insulin secretion from beta cells, so elevated visfatin could be a protective response.
  • Cost and accessibility: Currently, visfatin measurement is not widely available in routine clinical labs, and the cost may be prohibitive for large-scale screening. However, as demand grows and assays improve, this may change.

Future Directions

Future research should focus on standardizing visfatin assays and establishing robust reference ranges across diverse populations. Large prospective cohorts are needed to determine whether visfatin adds incremental predictive value to existing risk models, especially when combined with genetic and other omics data. Additionally, investigations into visfatin as a therapeutic target are warranted. Small molecule inhibitors of NAMPT are in development for cancer, and their potential repurposing for metabolic diseases could be explored—though with caution given the essential role of NAMPT in normal physiology.

The integration of visfatin with other biomarkers, such as adiponectin, leptin, and inflammatory cytokines, may yield a composite profile that better captures the complex pathophysiology of diabetes. Machine learning approaches could help identify patterns that predict progression or complications. For instance, a visfatin/adiponectin ratio has been proposed as a marker of insulin resistance.

Furthermore, the role of visfatin in specific diabetes subtypes—such as latent autoimmune diabetes in adults (LADA) or monogenic diabetes—remains largely unexplored. Understanding visfatin biology in these contexts could lead to more tailored therapeutic strategies. Epigenetic regulation of visfatin expression, such as DNA methylation changes, also warrants investigation as a potential early biomarker.

Conclusion

Serum visfatin holds promise as a biomarker for inflammatory and metabolic dysregulation in diabetes. Its dual role in inflammation and metabolism makes it a valuable tool for improving disease management and outcomes. Elevated visfatin levels reflect the chronic low-grade inflammation and insulin resistance that underpin type 2 diabetes, and they may predict future disease and complications. However, significant challenges related to assay standardization, confounding factors, and clinical validation must be addressed before visfatin can be incorporated into routine care. As research advances, visfatin may become an integral part of personalized treatment approaches for diabetic patients, alongside other emerging biomarkers. For now, it remains a compelling molecule that bridges the worlds of metabolism and immunity, offering insights that go beyond traditional glycemic markers.

For further reading on adipokines in diabetes, see this comprehensive review: Adipokines and Inflammation in Obesity and Diabetes. Additional information on NAMPT biology can be found at NAMPT and Its Role in Metabolism and Inflammation. Another useful resource is the meta-analysis of visfatin levels in type 2 diabetes that provides aggregated evidence for its clinical utility.